Impact of cigarette smoke exposure on host-bacterial pathogen interactions

European Respiratory Journal

Volumn 39, Issue 2, 2012, Pages 467-477

  Garmendia, J ^a,b,c   Morey, P ^a,b   Bengoechea, J A ^a,b,c  

^a Fundacion Caubet Cimera   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c CSIC   (Spain)

Author keywords

Airway mucociliary clearance; Chronic obstructive pulmonary disease; Corticosteroids; Infectious diseases; Inflammation; Tobacco smoking

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ASCORBIC ACID; BRONCHODILATING AGENT; CIGARETTE SMOKE; CORTICOSTEROID; CYSTATIN; DEXAMETHASONE; ELAFIN; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUTICASONE PROPIONATE; FLUTICASONE PROPIONATE PLUS SALMETEROL; INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MUCOLYTIC AGENT; OXYGEN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PROTEINASE INHIBITOR; RESVERATROL; ROLIPRAM; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AIRWAY OBSTRUCTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CHRONIC RESPIRATORY TRACT DISEASE; DETERIORATION; DISEASE EXACERBATION; EXPOSURE; HOST PATHOGEN INTERACTION; HUMAN; INFECTION RISK; INFLAMMATION; LOWER RESPIRATORY TRACT; LUNG CANCER; LUNG EMPHYSEMA; LUNG FIBROSIS; LUNG FUNCTION; MICROBIAL COLONIZATION; MICROFLORA; MUCUS SECRETION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; RESPIRATORY TRACT INFECTION; REVIEW; SMOKING; UPPER RESPIRATORY TRACT;

HOST-PATHOGEN INTERACTIONS; HUMANS; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING;

EID: 84856736136     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00061911     Document Type: Review

References (134)

1. García-Rodríguez JA, Fresnadillo Martínez MJ. Dynamics of nasopharyngeal colonization by potential respiratory pathogens. J Antimicrob Chemother 2002; 50: Suppl. S2, 59-73.
2. Voges M, Bachmann V, Kammerer R, et al. CEACAM1 recognition by bacterial pathogens is species-specific. BMC Microbiol 2010; 10: 117.
3. Taylor JD. COPD and the response of the lung to tobacco smoke exposure. Pulm Pharmacol Ther 2010; 23: 376-383.
4. Fereol S, Fodil R, Pelle G, et al. Cell mechanics of alveolar epithelial cells (AECs) and macrophages (AMs). Respir Physiol Neurobiol 2008; 163: 3-16.
5. Castranova V, Huffman LJ, Judy DJ, et al. Enhancement of nitric oxide production by pulmonary cells following silica exposure. Environ Health Perspect 1998; 106: Suppl. 5, 1165-1169. (Pubitemid 28554522)
6. Chaudhuri N, Sabroe I. Basic science of the innate immune system and the lung. Paediatr Respir Rev 2008; 9: 236-242.
7. Mason RJ. Biology of alveolar type II cells. Respirology 2006; 11: S12-S15.
8. Rubovitch V, Gershnabel S, Kalina M. Lung epithelial cells modulate the inflammatory response of alveolar macrophages. Inflammation 2007; 30: 236-243. (Pubitemid 350264458)
9. Zhang P, Summer WR, Bagby GJ, et al. Innate immunity and pulmonary host defense. Immunol Rev 2000; 173: 39-51. (Pubitemid 30095209)
10. Naito M. Macrophage differentiation and function in health and disease. Pathol Int 2008; 58: 143-155. (Pubitemid 351190168)
11. Bals R, Hiemstra PS. Innate immunity in the lung: how epithelial cells fight against respiratory pathogens. Eur Respir J 2004; 23: 327-333. (Pubitemid 38195522)
12. Borgerding M, Klus H. Analysis of complex mixtures - cigarette smoke. Exp Toxicol Pathol 2005; 57: 43-73. (Pubitemid 40884483)
13. Ling SH, van Eeden SF. Particulate matter air pollution exposure: role in the development and exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2009; 4: 233-243.
14. Larsson L, Szponar B, Ridha B, et al. Identification of bacterial and fungal components in tobacco and tobacco smoke. Tob Induc Dis 2008; 4: 4.
15. Pauly JL, Smith LA, Rickert MH, et al. Review: Is lung inflammation associated with microbes and microbial toxins in cigarette tobacco smoke? Immunol Res 2010; 46: 127-136.
16. Sapkota AR, Berger S, Vogel TM. Human pathogens abundant in the bacterial metagenome of cigarettes. Environ Health Perspect 2010; 118: 351-356.
17. Arcavi L, Benowitz NL. Cigarette smoking and infection. Arch Intern Med 2004; 164: 2206-2216. (Pubitemid 39452980)
18. MacNee W. Pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 258-266. (Pubitemid 41566933)
19. Barnes PJ. Mediators of chronic obstructive pulmonary disease. Pharmacol Rev 2004; 56: 515-548. (Pubitemid 39658462)
20. Cosío MG, Saetta M, Agustí A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med 2009; 360: 2445-2454.
21. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29: 1224-1238. (Pubitemid 46895385)
22. Barnes PJ. Prevention of death in COPD. N Engl J Med 2007; 356: 2211.
23. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
24. Hansel TT, Barnes PJ. New drugs for exacerbations of chronic obstructive pulmonary disease. Lancet 2009; 374: 744-755.
25. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2009; 41: 631-638.
26. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 2645-2653. (Pubitemid 38787999)
27. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008; 358: 716-727.
28. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001; 14: 336-363. (Pubitemid 32294674)
29. Mehta H, Nazzal K, Sadikot RT. Cigarette smoking and innate immunity. Inflamm Res 2008; 57: 497-503.
30. Maunders H, Patwardhan S, Phillips J, et al. Human bronchial epithelial cell transcriptome: gene expression changes following acute exposure to whole cigarette smoke in vitro. Am J Physiol Lung Cell Mol Physiol 2007; 292: 1248-1256.
31. Olivera DS, Boggs SE, Beenhouwer C, et al. Cellular mechanisms of mainstream cigarette smoke-induced lung epithelial tight junction permeability changes in vitro. Inhal Toxicol 2007; 19: 13-22. (Pubitemid 44863600)
32. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002; 2: 372-377. (Pubitemid 37328760)
33. 2 and host defence against Moraxella catarrhalis infection in human airway epithelial cells. Respirology 2011; 16: 508-516.
34. Honda Y, Takahashi H, Kuroki Y, et al. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996; 109: 1006-1009.
35. Droemann D, Goldmann T, Tiedje T, et al. Toll-like receptor 2 expression is decreased on alveolar macrophages in cigarette smokers and COPD patients. Respir Res 2005; 6: 68.
36. Regueiro V, Campos MA, Pons J, et al. The uptake of a Klebsiella pneumoniae capsule polysaccharide mutant triggers an inflammatory response by human airway epithelial cells. Microbiology 2006; 152: 555-566. (Pubitemid 43210686)
37. Snelgrove RJ, Jackson PL, Hardison MT, et al. A critical role for LTA4H in limiting chronic pulmonary neutrophilic inflammation. Science 2010; 330: 90-94.
38. Stringer KA, Tobias M, O'Neill HC, et al. Cigarette smoke extract-induced suppression of caspase-3-like activity impairs human neutrophil phagocytosis. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1572-L1579. (Pubitemid 47077373)
39. Berenson CS, Garlipp MA, Grove LJ, et al. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis 2006; 194: 1375-1384. (Pubitemid 44706505)
40. Hodge S, Hodge G, Ahern J, et al. Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2007; 37: 748-755. (Pubitemid 350211645)
41. Martí-Lliteras P, Regueiro V, Morey P, et al. Nontypeable Haemophilus influenzae clearance by alveolar macrophages is impaired by exposure to cigarette smoke. Infect Immun 2009; 77: 4232-4242.
42. Taylor AE, Finney-Hayward TK, Quint JK, et al. Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J 2010; 35: 1039-1047.
43. MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol 2001; 429: 195-207. (Pubitemid 33043996)
44. MacNee W, Rahman I. Is oxidative stress central to the pathogenesis of chronic obstructive pulmonary disease? Trends Mol Med 2001; 7: 55-62. (Pubitemid 33718642)
45. MacNee W. Oxidants/antioxidants and chronic obstructive pulmonary disease: pathogenesis to therapy. Novartis Found Symp 2001; 234: 169-185.
46. Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann NY Acad Sci 1993; 686: 12-27.
47. Shim JJ, Dabbagh K, Ueki IF, et al. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am J Physiol Lung Cell Mol Physiol 2001; 280: 134-140.
48. Gensch E, Gallup M, Sucher A, et al. Tobacco smoke control of mucin production in lung cells requires oxygen radicals AP-1 and JNK. J Biol Chem 2004; 279: 39085-39093. (Pubitemid 39296071)
49. Ferson M, Edwards A, Lind A, et al. Low natural killer-cell activity and immunoglobulin levels associated with smoking in human subjects. Int J Cancer 1979; 23: 603-609. (Pubitemid 9168661)
50. González-Quintela A, Alende R, Gude F, et al. Serum levels of immunoglobulins (IgG, IgA, IgM) in a general adult population and their relationship with alcohol consumption, smoking and common metabolic abnormalities. Clin Exp Immunol 2008; 151: 42-50. (Pubitemid 350230994)
51. Saetta M, Baraldo S, Corbino L, et al. CD8+ve cells in the lungs of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160: 711-717. (Pubitemid 29380694)
52. Bratke K, Klug M, Bier A, et al. Function-associated surface molecules on airway dendritic cells in cigarette smokers. Am J Respir Cell Mol Biol 2008; 38: 655-660. (Pubitemid 351841566)
53. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 165: 1404-1409. (Pubitemid 34522945)
54. Chrysofakis G, Tzanakis N, Kyriakoy D, et al. Perforin expression and cytotoxic activity of sputum CD8+ lymphocytes in patients with COPD. Chest 2004; 125: 71-76. (Pubitemid 38114566)
55. Knobloch J, Schild K, Jungck D, et al. The T-helper cell type 1 immune response to Gram-negative bacterial infections is impaired in COPD. Am J Respir Crit Care Med 2011; 183: 204-214.
56. Brook I, Gober AE. Recovery of potential pathogens and interfering bacteria in the nasopharynx of otitis media-prone children and their smoking and nonsmoking parents. Arch Otolaryngol Head Neck Surg 2005; 131: 509-512. (Pubitemid 40989608)
57. Brook I, Gober AE. Effect of smoking cessation on the microbial flora. Arch Otolaryngol Head Neck Surg 2007; 133: 135-138. (Pubitemid 46294113)
58. Bagaitkar J, Demuth DR, Daep CA, et al. Tobacco upregulates P. gingivalis fimbrial proteins which induce TLR2 hyposensitivity. PLoS One 2010; 5: e9323.
59. Bagaitkar J, Williams LR, Renaud DE, et al. Tobacco-induced alterations to Porphyromonas gingivalis-host interactions. Environ Microbiol 2009; 11: 1242-1253.
60. El Ahmer OR, Essery SD, Saadi AT, et al. The effect of cigarette smoke on adherence of respiratory pathogens to buccal epithelial cells. FEMS Immunol Med Microbiol 1999; 23: 27-36. (Pubitemid 29074358)
61. Bagaitkar J, Demuth DR, Scott DA. Tobacco use increases susceptibility to bacterial infection. Tob Induc Dis 2008; 4: 12.
62. Palmer RM, Wilson RF, Hasan AS, et al. Mechanisms of action of environmental factors-tobacco smoking. J Clin Periodontol 2005; 32: 180-195. (Pubitemid 41391064)
63. Zambon JJ, Grossi SG, Machtei EE, et al. Cigarette smoking increases the risk for subgingival infection with periodontal pathogens. J Periodontol 1996; 67: 1050-1054. (Pubitemid 126613085)
64. van der Weijden GA, de Slegte C, Timmerman MF, et al. Periodontitis in smokers and non-smokers: intra-oral distribution of pockets. J Clin Periodontol 2001; 28: 955-960. (Pubitemid 33755479)
65. Haffajee AD, Socransky SS. Relationship of cigarette smoking to the subgingival microbiota. J Clin Periodontol 2001; 28: 377-388. (Pubitemid 33755454)
66. Shchipkova AY, Nagaraja HN, Kumar PS. Subgingival microbial profiles of smokers with periodontitis. J Dent Res 2010; 89: 1247-1253.
67. van Winkelhoff AJ, Bosch-Tijhof CJ, Winkel EG, et al. Smoking affects the subgingival microflora in periodontitis. J Periodontol 2001; 72: 666-671. (Pubitemid 33606332)
68. Delima SL, McBride RK, Preshaw PM, et al. Response of subgingival bacteria to smoking cessation. J Clin Microbiol 2010; 48: 2344-2349.
69. Goldstein-Daruech N, Cope EK, Zhao KQ, et al. Tobacco smoke mediated induction of sinonasal microbial biofilms. PLoS One 2011; 6: e15700.
70. Aronson MD, Weiss ST, Ben RL, et al. Association between cigarette smoking and acute respiratory tract illness in young adults. JAMA 1982; 248: 181-183. (Pubitemid 12078153)
71. Greenberg D, Givon-Lavi N, Broides A, et al. The contribution of smoking and exposure to tobacco smoke to Streptococcus pneumoniae and Haemophilus influenzae carriage in children and their mothers. Clin Infect Dis 2006; 42: 897-903.
72. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk factor for meningococcal disease. Pediatr Infect Dis J 1997; 16: 979-983. (Pubitemid 27452317)
73. Iles K, Poplawski NK, Couper RT. Passive exposure to tobacco smoke and bacterial meningitis in children. J Paediatr Child Health 2001; 37: 388-391. (Pubitemid 32772493)
74. Jones LL, Hashim A, McKeever T, et al. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res 2011; 12: 5.
75. Sethi S, Mallia P, Johnston SL. New paradigms in the pathogenesis of chronic obstructive pulmonary disease II. Proc Am Thorac Soc 2009; 6: 532-534.
76. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471.
77. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 2355-2365.
78. Rao VK, Krasan GP, Hendrixson DR, et al. Molecular determinants of the pathogenesis of disease due to non-typable Haemophilus influenzae. FEMS Microbiol Rev 1999; 23: 99-129. (Pubitemid 29189244)
79. Mukundan D, Ecevit Z, Patel M, et al. Pharyngeal colonization dynamics of Haemophilus influenzae and Haemophilus haemolyticus in healthy adult carriers. J Clin Microbiol 2007; 45: 3207-3217. (Pubitemid 47585641)
80. Samuelson A, Freijd A, Jonasson J, et al. Turnover of non-encapsulated Haemophilus influenzae in the nasopharynges of otitis-prone children. J Clin Microbiol 1995; 33: 2027-2031.
81. Margolis E, Yates A, Levin BR. The ecology of nasal colonization of Streptococcus pneumoniae, Haemophilus influenzae and Staphylococcus aureus: the role of competition and interactions with host's immune response. BMC Microbiol 2010; 10: 59.
82. Ratner AJ, Lysenko ES, Paul MN, et al. Synergistic proinflammatory responses induced by polymicrobial colonization of epithelial surfaces. Proc Natl Acad Sci USA 2005; 102: 3429-3434. (Pubitemid 40328062)
83. Lysenko ES, Clarke TB, Shchepetov M, et al. Nod1 signaling overcomes resistance of S. pneumoniae to opsonophagocytic killing. PLoS Pathog 2007; 3: e118.
84. Lysenko ES, Ratner AJ, Nelson AL, et al. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog 2005; 1: e1.
85. Lysenko ES, Lijek RS, Brown SP, et al. Within-host competition drives selection for the capsule virulence determinant of Streptococcus pneumoniae. Curr Biol 2010; 20: 1222-1226.
86. Regueiro V, Campos MA, Morey P, et al. Lipopolysaccharide-binding protein and CD14 are increased in the bronchoalveolar lavage fluid of smokers. Eur Respir J 2009; 33: 273-281.
87. Morey P, Cano V, Martí-Lliteras P, et al. Evidence for a non-replicative intracellular stage of nontypable Haemophilus influenzae in epithelial cells. Microbiology 2011; 157: 234-250.
88. King PT, Ngui J, Farmer MW, et al. Cytotoxic T lymphocyte and natural killer cell responses to non-typeable Haemophilus influenzae. Clin Exp Immunol 2008; 152: 542-551. (Pubitemid 351661515)
89. de Bree GJ, Daniels H, Schilfgaarde M, et al. Characterization of CD4+ memory T cell responses directed against common respiratory pathogens in peripheral blood and lung. J Infect Dis 2007; 195: 1718-1725. (Pubitemid 46799231)
90. Kadioglu A, Weiser JN, Paton JC, et al. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008; 6: 288-301. (Pubitemid 351404773)
91. Almirall J, Bolibar I, Balanzo X, et al. Risk factors for community-acquired pneumonia in adults: a population-based case-control study. Eur Respir J 1999; 13: 349-355. (Pubitemid 29086832)
92. Almirall J, Gonzalez CA, Balanzo X, et al. Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 1999; 116: 375-379. (Pubitemid 29382121)
93. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and invasive pneumococcal disease. Active Bacterial Core Surveillance Team. N Engl J Med 2000; 342: 681-689. (Pubitemid 30131420)
94. Vander Top EA, Wyatt TA, Gentry-Nielsen MJ. Smoke exposure exacerbates an ethanol-induced defect in mucociliary clearance of Streptococcus pneumoniae. Alcohol Clin Exp Res 2005; 29: 882-887. (Pubitemid 40686559)
95. Phipps JC, Aronoff DM, Curtis JL, et al. Cigarette smoke exposure impairs pulmonary bacterial clearance and alveolar macrophage complement-mediated phagocytosis of Streptococcus pneumoniae. Infect Immun 2010; 78: 1214-1220.
96. Parameswaran GI, Wrona CT, Murphy TF, et al. Moraxella catarrhalis acquisition, airway inflammation and protease-antiprotease balance in chronic obstructive pulmonary disease. BMC Infect Dis 2009; 9: 178.
97. Amedei A, Della Bella C, Niccolai E, et al. Moraxella catarrhalis-specific Th1 cells in BAL fluids of chronic obstructive pulmonary disease patients. Int J Immunopathol Pharmacol 2009; 22: 979-990.
98. Drannik AG, Pouladi MA, Robbins CS, et al. Impact of cigarette smoke on clearance and inflammation after Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2004; 170: 1164-1171. (Pubitemid 39577373)
99. Cantin AM, Hanrahan JW, Bilodeau G, et al. Cystic fibrosis transmembrane conductance regulator function is suppressed in cigarette smokers. Am J Respir Crit Care Med 2006; 173: 1139-1144. (Pubitemid 43726895)
100. Martínez-Solano L, Macía MD, Fajardo A, et al. Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease. Clin Infect Dis 2008; 47: 1526-1533.
101. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality. Arch Intern Med 1994; 154: 2417-2422.
102. Bates MN, Khalakdina A, Pai M, et al. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 335-342. (Pubitemid 46333932)
103. Feng Y, Kong Y, Barnes PF, et al. Exposure to cigarette smoke inhibits the pulmonary T-cell response to influenza virus and Mycobacterium tuberculosis. Infect Immun 2011; 79: 229-237.
104. Varma-Basil M, Dwivedi SK, Kumar K, et al. Role of Mycoplasma pneumoniae infection in acute exacerbations of chronic obstructive pulmonary disease. J Med Microbiol 2009; 58: 322-326.
105. Kariya C, Chu HW, Huang J, et al. Mycoplasma pneumoniae infection and environmental tobacco smoke inhibit lung glutathione adaptive responses and increase oxidative stress. Infect Immun 2008; 76: 4455-4462.
106. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006; 27: 413-426. (Pubitemid 43185854)
107. Barnes PJ, Stockley RA. COPD: current therapeutic interventions and future approaches. Eur Respir J 2005; 25: 1084-1106. (Pubitemid 40823786)
108. Bellanger AP, Millon L, Khoufache K, et al. Aspergillus fumigatus germ tube growth and not conidia ingestion induces expression of inflammatory mediator genes in the human lung epithelial cell line A549. J Med Microbiol 2009; 58: 174-179.
109. Mogensen TH, Berg RS, Paludan SR, et al. Mechanisms of dexamethasone-mediated inhibition of Toll-like receptor signaling induced by Neisseria meningitidis and Streptococcus pneumoniae. Infect Immun 2008; 76: 189-197.
110. Skornik WA, Dressler DP. The effects of short-term steroid therapy on lung bacterial clearance and survival in rats. Ann Surg 1974; 179: 415-421.
111. Satoh S, Oishi K, Iwagaki A, et al. Dexamethasone impairs pulmonary defence against Pseudomonas aeruginosa through suppressing iNOS gene expression and peroxynitrite production in mice. Clin Exp Immunol 2001; 126: 266-273. (Pubitemid 32995141)
112. Imasato A, Desbois-Mouthon C, Han J, et al. Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of Toll-like receptor 2. J Biol Chem 2002; 277: 47444-47450. (Pubitemid 36159261)
113. Komatsu K, Jono H, Lim JH, et al. Glucocorticoids inhibit nontypeable Haemophilus influenzae-induced MUC5AC mucin expression via MAPK phosphatase-1-dependent inhibition of p38 MAPK. Biochem Biophys Res Commun 2008; 377: 763-768.
114. Li JD. Exploitation of host epithelial signaling networks by respiratory bacterial pathogens. J Pharmacol Sci 2003; 91: 1-7.
115. Shuto T, Imasato A, Jono H, et al. Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced Toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase. J Biol Chem 2002; 277: 17263-17270. (Pubitemid 34967761)
116. Barbier M, Agustí A, Albertí S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008; 32: 1283-1288.
117. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk ofhospitalization for pneumonia. Am J Respir Crit Care Med 2007; 176: 162-166. (Pubitemid 47057852)
118. Barnes PJ. Reduced histone deacetylase in COPD: clinical implications. Chest 2006; 129: 151-155. (Pubitemid 43265256)
119. Barnes PJ. ABC of chronic obstructive pulmonary disease. Future treatments. BMJ 2006; 333: 246-248. (Pubitemid 44406718)
120. Barnes PJ. Novel signal transduction modulators for the treatment of airway diseases. Pharmacol Ther 2006; 109: 238-245. (Pubitemid 41740824)
121. Barnes PJ, Hansel TT. Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 2004; 364: 985-996. (Pubitemid 39208462)
122. Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005; 2: 334-339. (Pubitemid 41699692)
123. Marwick JA, Caramori G, Stevenson CS, et al. Inhibition of PI3Kδ restores glucocorticoid function in smoking-induced airway inflammation inmice. Am J Respir Crit Care Med 2009; 179: 542-548.
124. 2-adrenergic receptor agonist. Am J Respir Cell Mol Biol 2004; 30: 605-612.
125. 2-adrenergic receptor agonist and corticosteroid of Staphylococcus aureus-induced airway epithelial inflammatory mediator production. Am J Physiol Lung Cell Mol Physiol 2006; 291: L11-L18.
126. Dowling RB, Johnson M, Cole PJ, et al. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998; 11: 86-90. (Pubitemid 28081800)
127. Maris NA, Florquin S, van't Veer C, et al. Inhalation of β-2 agonists impairs the clearance of nontypable Haemophilus influenzae from the murine respiratory tract. Respir Res 2006; 7: 57.
128. Lu CC, Lai HC, Hsieh SC, et al. Resveratrol ameliorates Serratia marcescens-induced acute pneumonia in rats. J Leukoc Biol 2008; 83: 1028-1037.
129. Wang WB, Lai HC, Hsueh PR, et al. Inhibition of swarming and virulence factor expression in Proteus mirabilis by resveratrol. J Med Microbiol 2006; 55: 1313-1321.
130. Zaidi SF, Ahmed K, Yamamoto T, et al. Effect of resveratrol on Helicobacter pylori-induced interleukin-8 secretion, reactive oxygen species generation and morphological changes in human gastric epithelial cells. Biol Pharm Bull 2009; 32: 1931-1935.
131. Docherty JJ, Fu MM, Tsai M. Resveratrol selectively inhibits Neisseria gonorrhoeae and Neisseria meningitidis. J Antimicrob Chemother 2001; 47: 243-244. (Pubitemid 32149540)
132. Bishop BL, Duncan MJ, Song J, et al. Cyclic AMP-regulated exocytosis of Escherichia coli from infected bladder epithelial cells. Nat Med 2007; 13: 625-630. (Pubitemid 46828483)
133. Dowling RB, Johnson M, Cole PJ, et al. The effect of rolipram, a type IV phosphodiesterase inhibitor, on Pseudomonas aeruginosa infection of respiratory mucosa. J Pharmacol Exp Ther 1997; 282: 1565-1571. (Pubitemid 27408342)
134. Soares AC, Souza DG, Pinho V, et al. Impaired host defense to Klebsiella pneumoniae infection in mice treated with the PDE4 inhibitor rolipram. Br J Pharmacol 2003; 140: 855-862. (Pubitemid 37464067)